Jazz Pharmaceuticals Director Laura Hamill Files Form 144 to Sell $857K in Common Shares
Jazz Pharmaceuticals plc
Subscribe to track JAZZ
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
📋 Form 144 Proposed Sale Notice Issuer: Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Insider: Laura Hamill (Director) Shares to Sell: 3,507 Common Shares Aggregate Market Value: $857,602.00 (~$244.54/share) Origin of Shares: Restricted Stock Vesting (08/28/2026) Approximate Sale Date: 08/31/2026 Broker: E*TRADE Financial Corporation
Comprehensive Analysis
Form 144 Analysis: Jazz Pharmaceuticals plc
- Insider: Laura Hamill, Director
- Planned Transaction: Notice of proposed sale of 3,507 shares of Common Stock under Rule 144.
- Estimated Total Value: $857,602.00 (implied price of ~$244.54 per share).
- Acquisition Details: The shares were recently acquired on August 28, 2026, via restricted stock vesting as part of director equity compensation.
- Market Impact & Significance: Low. The proposed transaction represents a routine monetization of vested equity compensation and is immaterial relative to the issuer's total outstanding share count of approximately 64.9 million shares.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.